UBS analyst Kavya Deshpande initiated coverage of Elekta (EKTAY) with a Sell rating and SEK 34 price target The firm’s analysis suggests the radiotherapy market is slowing meaningfully and that Elekta is unlikely to compensate with share gains.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EKTAY: